Top

Gepubliceerd in:

01-07-2014

Pneumokokkenziekte

Auteurs: Drs. Marieke Bolkenbaas, Prof. dr. Marc (J.M.) Bonten

Gepubliceerd in: Bijblijven | Uitgave 7/2014

Samenvatting

Pneumokokkeninfecties komen frequent voor en vormen wereldwijd een belangrijke oorzaak van morbiditeit en mortaliteit. De incidentie is het hoogst onder jonge kinderen en ouderen; bij deze groepen is bovendien het risico op sterfte of complicaties ten gevolge van de infectie het grootst. Behandeling wordt gecompliceerd door stijgende resistentie van pneumokokken voor de meest gebruikte antibiotische middelen. Sinds 2006 worden in Nederland baby’s via het Rijksvaccinatieprogramma gevaccineerd tegen pneumokokken, waarbij ook een beschermend effect te verwachten is op andere risicogroepen. In een recente grote Nederlandse vaccinatietrial (CAPiTA) bleek pneumokokkenvaccinatie effectief in het voorkomen van pneumokokkenpneumonie en invasieve pneumokokkenziekte bij ouderen.

vorige artikel Antimicrobiële resistentie: vechten tegen de bierkaai?

Labout JA, Duijts L, Arends LR, Jaddoe VW, Hofman A, De GR, et al. Factors associated with pneumococcal carriage in healthy Dutch infants: the generation R study. J Pediatr. 2008 Dec;153(6):771–6.PubMedCrossRef

Gils EJ van, Veenhoven RH, Rodenburg GD, Hak E, Sanders EA. Effect of 7-valent pneumococcal conjugate vaccine on nasopharyngeal carriage with Haemophilus influenzae and Moraxella catarrhalis in a randomized controlled trial. Vaccine. 2011 Oct 13;29(44):7595–8.PubMedCrossRef

Goldblatt D, Hussain M, Andrews N, Ashton L, Virta C, Melegaro A, et al. Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study. J Infect Dis. 2005 Aug 1;192(3):387–93.

Palmu AA, Kaijalainen T, Saukkoriipi A, Leinonen M, Kilpi TM. Nasopharyngeal carriage of Streptococcus pneumoniae and pneumococcal urine antigen test in healthy elderly subjects. Scand J Infect Dis. 2012 Jun;44(6):433–8.

Wolleswinkel-van den Bosch JH, Stolk EA, François M, Gasparini R, Brosa M. The health care burden and societal impact of acute otitis media in seven European countries: results of an Internet survey. Vaccine. 2010 Nov 19;28 (Suppl 6):G39–G52.

Kung YH, Chiu NC, Lee KS, Chang L, Huang DT, Huang FY, et al. Bacterial etiology of acute otitis media in the era prior to universal pneumococcal vaccination in Taiwanese children. J Microbiol Immunol Infect. 2013 Sep 27.

Block SL. Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media. Pediatr Infect Dis J. 1997 Apr;16(4):449–56.PubMedCrossRef

Damoiseaux RA, Balen FA van, Leenheer WA, Kolnaar BG. NHG-Standaard Otitis media acuta (tweede herziening). Huisarts Wet. 2006;49(12):615–21.

Bjerre LM, Verheij TJ, Kochen MM. Antibiotics for community acquired pneumonia in adult outpatients. Cochrane Database Syst Rev. 2009;(4):CD002109.

Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007 Mar 1;44 (Suppl 2):S27–S72.

World Health Organization. Pneumonia. Geneva, 2013 (report No.: 331).

World Health Organization. The top 10 causes of death. Geneva, 2013 (report No.: 310).

Woodhead MA, Macfarlane JT, McCracken JS, Rose DH, Finch RG. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet. 1987 Mar 21;1(8534):671–4.PubMedCrossRef

Eerden MM van der, Vlaspolder F, Graaff CS de, Groot T, Jansen HM, Boersma WG. Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 2005 Apr;24(4):241–9.PubMedCrossRef

Bohte R, Furth R van, Broek PJ van den. Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital. Thorax. 1995 May;50(5):543–7.PubMedCrossRefPubMedCentral

Woodhead M. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur Respir J. Suppl 2002 Jul;36:20s-7s.

Said MA, Johnson HL, Nonyane BA, Oria-Knoll M, O’Brien KL, Andreo F, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One. 2013;8(4):e6027–3.CrossRef

Jansen AG, Rodenburg GD, Greeff SC de, et al. Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits. Vaccine. 2009 Apr 14;27(17):2394–401.

Harboe ZB, Thomsen RW, Riis A, Valentiner-Branth P, Christensen JJ, Lambertsen L, et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med. 2009 May 26;6(5):e1000081.

Sinclair A, Xie X, Teltscher M, Dendukuri N. Systematic review and meta-analysis of a urine-based pneumococcal antigen test for diagnosis of community-acquired pneumonia caused by Streptococcus pneumoniae. J Clin Microbiol 2013 Jul;51(7):2303–10.

Verheij TJ, Hopstaken RM, Prins JM, et al. NHG-Standaard Acuut hoesten (Eerste herziening). Huisarts Wet. 2011 Feb 1;54(2):68–92.

Wiersinga WJ, Bonten MJ, Boersma WG, Jonkers RE, Aleva RM, Kullberg BJ, et al. SWAB/NVALT (Dutch Working Party on Antibiotic Policy and Dutch Association of Chest Physicians) guidelines on the management of community-acquired pneumonia in adults. Neth J Med. 2012 Mar;70(2):90–101.PubMed

SWAB. NethMap 2012 - Consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands. Nijmegen, 2012.

ISIS-AR data. Geraadpleegd via www isis-web.nl op 21 april 2014.

European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2012. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC, 2013.

Wright AE, Parry M, Colebrook L, Dodgson RW. Observation on prophylactic inoculation against pneumococcus infections, and on the results which have been achieved by it. Lancet. 1914 Jul 4;183(4714):1–10.

Rijkers GT, Sanders EA, Breukels MA, Zegers BJ. Infant B cell responses to polysaccharide determinants. Vaccine. 1998 Aug;16(14-15):1396–400.PubMedCrossRef

Clutterbuck EA, Lazarus R, Yu LM, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis. 2012 May 1;205(9):1408–16.

Jackson LA, Janoff EN. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis. 2008 Nov 15;47(10):1328–38.

Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics. 1998 Apr;101(4 Pt 1):604–11.

Pletz MW, Maus U, Krug N, Welte T, Lode H. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents. 2008 Sep;32(3):199–206.PubMedCrossRef

Gezondheidsraad. Vaccinatie tegen pneumokokken bij ouderen en risicogroepen. Den Haag, 2003 (rapport nr. 2003/10).

Gezondheidsraad. Vaccinatie van zuigelingen tegen pneumokokkeninfecties (3). Den Haag, 2013(rapport nr. 2013/28).

Spijkerman J, Veenhoven RH, Wijmenga-Monsuur AJ, et al. Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial. JAMA. 2013 Sep 4;310(9):930–7.

Rozenbaum MH, Sanders EA, Hoek AJ van, et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ. 2010;340:c2509.

Rodenburg GD, Greeff SC de, Jansen AG, et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis. 2010 May;16(5):816–23.PubMedCrossRefPubMedCentral

Elberse KE, Heide HG van der, Witteveen S, et al. Changes in the composition of the pneumococcal population and in IPD incidence in The Netherlands after the implementation of the 7-valent pneumococcal conjugate vaccine. Vaccine. 2012 Dec 14;30(52):7644–51.

Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011 Oct;11(10):760–8.PubMedCrossRef

Rudnick W, Liu Z, Shigayeva A, Low DE, Green K, Plevneshi A, et al. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011. Vaccine. 2013 Dec 2;31(49):5863–71.

Simonsen L, Taylor RJ, Young-Xu Y, Haber M, May L, Klugman KP. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio. 2011;2(1):e00309-e00310.

Titel: Pneumokokkenziekte
Auteurs: Drs. Marieke Bolkenbaas
Prof. dr. Marc (J.M.) Bonten
Publicatiedatum: 01-07-2014
Uitgeverij: Bohn Stafleu van Loghum
Gepubliceerd in: Bijblijven / Uitgave 7/2014
Print ISSN: 0168-9428
Elektronisch ISSN: 1876-4916
DOI: https://doi.org/10.1007/s12414-014-0054-1

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen

Andere artikelen Uitgave 7/2014

Gezondheidsraad: vaccinatiezorg verbreden naar individuele zorg

Mazelen

Antimicrobiële resistentie: vechten tegen de bierkaai?

Lymeziekte: valkuilen en misverstanden

Chronische hepatitis B en C, case-finding onder risicogroepen in de huisartspraktijk

Redactioneel ten geleide